A5090170824- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Dental Implant Techniques and Outcomes
- Lung Cancer Diagnosis and Treatment
- Periodontal Regeneration and Treatments
- Gene expression and cancer classification
- Sarcoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Oral and Maxillofacial Pathology
- Ferroptosis and cancer prognosis
- Cleft Lip and Palate Research
- Cancer Cells and Metastasis
- Gastrointestinal Tumor Research and Treatment
- Orthodontics and Dentofacial Orthopedics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Epigenetics and DNA Methylation
- HER2/EGFR in Cancer Research
- Ocular Disorders and Treatments
- Facial Trauma and Fracture Management
- Cancer therapeutics and mechanisms
- Advanced Proteomics Techniques and Applications
- NF-κB Signaling Pathways
Lund University
2012-2021
Medicon Village
2013-2020
Hallands sjukhus Halmstad
2016
Skåne University Hospital
2012-2013
Halmstad University
2007
Abstract Background Lung cancer is the worldwide leading cause of death from cancer. Tobacco usage major pathogenic factor, but all lung cancers are not attributable to smoking. Specifically, in never-smokers has been suggested represent a distinct disease entity compared arising smokers due differences etiology, natural history and response specific treatment regimes. However, genetic aberrations that differ between never-smokers’ carcinomas remain large extent unclear. Methods Unsupervised...
Abstract Lung cancer is the worldwide leading cause of death from and has been shown to be a heterogeneous disease at genomic level. To delineate landscape copy number alterations, amplifications, loss‐of‐heterozygosity (LOH), tumor ploidy copy‐neutral allelic imbalance in lung cancer, microarray‐based profiles 2,141 tumors cell lines including adenocarcinomas (AC, n = 1,206), squamous carcinomas (SqCC, 467), large ( 37) small (SCLC, 88) were assembled different repositories. Copy alteration...
IntroductionIn lung adenocarcinoma, the mutational spectrum is dominated by EGFR and KRAS mutations. Improved knowledge about genomic transcriptional alterations in between mutation-defined subgroups may identify genes involved disease development or progression. MethodsGenomic profiles from 457 adenocarcinomas, including 113 EGFR-mutated, 134 KRAS-mutated 210 KRAS-wild type tumors (EGFRwt/KRASwt), gene expression 914 309 192 KRAS-mutated, 413 EGFRwt/KRASwt tumors, were assembled different...
Objectives Among patients who underwent primary surgery for non-small cell lung cancer (NSCLC), recurrent disease is frequent and cannot be accurately predicted solely from TNM stage histopathological features. The aim of this study was to examine the association tumor markers in pre-operative serum with disease. Material methods Blood samples were collected prior 107 I-III adenocarcinoma surgically treated at Lund University hospital, Lund, Sweden, between 2005 2011. Carcinoembryonic...
Background: Lung cancer patients have a risk of recurrence even after curatively intended surgery. Cell-free circulating tumor DNA (ctDNA) and marker measurements are easily accessible through peripheral blood could potentially identify with worse prognosis. The aim this study was to examine ctDNA in pre-operative plasma the role markers serum for their predictive potential on recurrence. Methods: Mutation analysis by 26-gene targeted sequencing performed 157 lung adenocarcinomas (ACs) from...
In lung adenocarcinoma, EGFR and KRAS mutations dominate the mutational spectrum have clear therapeutic implications. We sought to determine whether transcriptional subgroups of clinical relevance exist within EGFR-mutated, KRAS-mutated, or wild-type (EGFRwt/KRASwt) adenocarcinomas.Gene expression profiles from 1,186 adenocarcinomas, including 215 84 219 EGFRwt/KRASwt tumors, were assembled divided into four discovery (n = 522) validation cohorts 664). Subgroups mutation groups identified by...
Characterization of molecules within important oncogenetic pathways may have future implications for development therapies and biomarkers in lung cancer. One such target is the tyrosine kinase receptor KIT (c‐KIT). We evaluated alterations expression its ligand, KITLG (also known as SCF), 72 clinical tumor specimens different histologies. Gene copy number, mRNA levels, protein were assayed using array‐based comparative genomic hybridization, real‐time quantitative reverse transcription PCR...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for risk stratification beyond tumor stage are needed. Gene expression-based AC subtypes such as the Cancer Genome Atlas Network (TCGA) terminal-respiratory unit (TRU), proximal-inflammatory (PI) and proximal-proliferative (PP) have been associated with prognosis, but show methodological limitations robust clinical use. We aimed to derive a platform independent single sample predictor (SSP)...
Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer Sweden. We describe and mutational profiles patients subjected to first 1.5 years treatment predictive MPS testing an autonomous regional health care region.Tumors from all with who had test January 2015 June 2016 Skåne region Sweden (1.3 million citizens) were included. Six hundred eleven tumors 599 profiled using targeted a 26-gene exon-focused panel. Data on disease...
Abstract The associated publication reports proteogenomic analysis of non-small cell lung cancer (NSCLC), where we identified molecular subtypes with distinct immune evasion mechanisms and therapeutic targets, validated our classification method in separate clinical cohorts. This protocol describes sections the bioinformatics multi-omics data, namely, data processing for panel sequencing, identification cancer- driver-related proteins proteomics proteogenomics search, machine learning-based...
Abstract The associated publication reports proteogenomic analysis of non-small cell lung cancer, where we identified molecular subtypes with distinct immune evasion mechanisms and therapeutic targets, validated our classification method in separate clinical cohorts. This protocol describes histological, tertiary lymphoid structure (TLS), immunohistochemical evaluation samples. Specifically, immunohistochemistry was performed for PD-L1, CD3, CD8 on tumor microarrays (TMAs) derived from...
Abstract The associated publication reports proteogenomic analysis of non-small cell lung cancer (NSCLC), where we identified molecular subtypes with distinct immune evasion mechanisms and therapeutic targets, validated our classification method in separate clinical cohorts. in-depth proteomic pointed to a potential role STK11 inactivation liver-specific signaling subsequent growth mechanisms. This protocol describes vitro validation the downstream effects STK11-AMPK on HNF1A FGL1 liver two lines.
Abstract The associated publication reports proteogenomic analysis of non-small cell lung cancer, where we identified molecular subtypes with distinct immune evasion mechanisms and therapeutic targets, validated our classification method in separate clinical cohorts. This protocol describes the sample preparation mass spectrometry (MS)-based in-depth rapid proteomic analyses tumor biopsy samples. We deployed single-pot solid-phase-enhanced (SP3). For analysis, used TMT labeling, followed by...
<p>Figure S2 - PDF file 95K, Differences in patterns of copy number gain and loss between EGFR-1/2 wt/wt-1/2 transcriptional subgroups</p>
<p>Figure S3A - PDF file 6934K, Expression pattern of EGFR-1/2 multicohort centroid genes across included adenocarcinoma cohorts</p>
<p>Supplementary References, Methods and Figure Legend - PDF file 160K, Supplementary Information with detailed information about data processing steps figure legends for supplementary figures</p>
<p>Figure S1 - PDF file 102K, Identification, characteristics and validation of transcriptional subgroups in EGFR-mutated EGFRwt/KRASwt tumors</p>